These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27665858)

  • 21. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
    Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
    J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
    Dvir D; Barbash IM; Torguson R; Badr S; Sardi GL; Laynez-Carnicero A; Ben-Dor I; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(3):128-33. PubMed ID: 23642502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice.
    Kim JH; Park KW; Lim WH; Shin DH; Chae IH; Choi DJ; Kim HS
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):349-59. PubMed ID: 24654284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry.
    Tarantini G; Facchin M; Capodanno D; Musumeci G; Saia F; Menozzi A; Meliga E; Mancone M; Lettieri C; Tamburino C
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):80-9. PubMed ID: 22511311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of long-term clinical outcome after successful implantation of Firebird sirolimus- and Taxus paclitaxel-eluting stents in Chinese population: analysis of a large single center registry.
    Dou KF; Xu B; Yang YJ; Chen JL; Qiao SB; Wang Y; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Chen J; Yuan JQ; You SJ; Li W; Gao RL
    Chin Med J (Engl); 2010 Apr; 123(7):810-5. PubMed ID: 20497669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
    Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
    JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
    Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of long-term clinical outcomes between sirolimus- and paclitaxel-eluting stents in real-world clinical practice.
    Naito R; Miyauchi K; Konishi H; Tsuboi S; Ogita M; Kasai T; Tamura H; Okazaki S; Daida H
    Heart Vessels; 2015 Nov; 30(6):746-51. PubMed ID: 25117761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Major adverse cardiac events in patients with moderate to severe renal insufficiency treated with first-generation drug-eluting stents.
    Sukhija R; Aronow WS; Palaniswamy C; Singh T; Sukhija R; Kalapatapu K; Mohan D; Pucillo AL; Sorbera C; Kakar P; Weiss MB; Lal P; Monsen CE
    Am J Cardiol; 2010 Feb; 105(3):293-6. PubMed ID: 20102937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.